Pseudovirion particle production by live poxvirus human immunodeficiency virus vaccine vector enhances humoral and cellular immune responses

被引:18
作者
Chen, XM
Rock, MT
Hammonds, J
Tartaglia, J
Shintani, A
Currier, J
Slike, B
Crowe, JE
Marovich, M
Spearman, P
机构
[1] Vanderbilt Univ, Sch Med, Dept Pediat, Nashville, TN 37232 USA
[2] Vanderbilt Univ, Sch Med, Dept Microbiol & Immunol, Nashville, TN 37232 USA
[3] Vanderbilt Univ, Sch Med, Dept Biostat, Nashville, TN 37232 USA
[4] Aventis Pasteur, Toronto, ON, Canada
[5] US Mil Acad, HIV Res Program, Rockville, MD USA
关键词
D O I
10.1128/JVI.79.9.5537-5547.2005
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Live-vector-based human immunodeficiency virus (HIV) vaccines are an integral part of a number of HIV vaccine regimens currently under evaluation. Live vectors that carry an intact gag gene are capable of eliciting HIV pseudovirion particle formation from infected host cells. The impact of pseudovirion particle formation on the immune response generated by live HIV vaccine vectors has not been established. In this study, a canarypox HIV vaccine candidate vector expressing HIV gag and env genes, vCP205, was modified by the introduction of a glycine-to-alanine coding change in the N-terminal myristylation site of gag to create Myr(-) vCP205. This substitution effectively eliminated particle formation without altering the level of protein production. vCP205 and Myr- vCP205 were then directly compared for the ability to induce HIV-specific immune responses in mice. The particle-competent vector vCP205 elicited higher levels of CD8(+) T-cell responses, as indicated by gamma interferon enzyme-linked immunospot (ELISPOT) assay and intracellular cytokine staining. Humoral responses to Gag and Env were also markedly higher from animals immunized with the particle-competent vector. Furthermore, HIV-specific CD4(+) T-cell responses were greater among animals immunized with the particle-competent vector. Using a human dendritic cell model of antigen presentation in vitro, vCP205 generated greater ELISPOT responses than Myr(-) vCP205. These results demonstrate that pseudovirion particle production by live-vector HIV vaccines enhances HIV-specific cellular and humoral immune responses.
引用
收藏
页码:5537 / 5547
页数:11
相关论文
共 49 条
[1]   Different patterns of immune responses but similar control of a simian-human immunodeficiency virus 89.6P mucosal challenge by modified vaccinia virus Ankara (MVA) and DNA/MVA vaccines [J].
Amara, RR ;
Villinger, F ;
Staprans, SI ;
Altman, JD ;
Montefiori, DC ;
Kozyr, NL ;
Xu, Y ;
Wyatt, LS ;
Earl, PL ;
Herndon, JG ;
McClure, HM ;
Moss, B ;
Robinson, HL .
JOURNAL OF VIROLOGY, 2002, 76 (15) :7625-7631
[2]   Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus type 1 vaccine with or without gp120: A phase 2 study in higher- and lower-risk volunteers [J].
Belshe, RB ;
Stevens, C ;
Gorse, GJ ;
Buchbinder, S ;
Weinhold, K ;
Sheppard, H ;
Stablein, D ;
Self, S ;
McNamara, J ;
Frey, S ;
Flores, J ;
Excler, JL ;
Klein, M ;
El Habib, R ;
Duliege, AM ;
Harro, C ;
Corey, L ;
Keefer, M ;
Mulligan, M ;
Wright, P ;
Celum, C ;
Judson, F ;
Mayer, K ;
McKirnan, D ;
Marmor, M ;
Woody, G .
JOURNAL OF INFECTIOUS DISEASES, 2001, 183 (09) :1343-1352
[3]   Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers [J].
Belshe, RB ;
Gorse, GJ ;
Mulligan, MJ ;
Evans, TG ;
Keefer, MC ;
Excler, JL ;
Duliege, AM ;
Tartaglia, J ;
Cox, WI ;
McNamara, J ;
Hwang, KL ;
Bradney, A ;
Montefiori, D ;
Weinhold, KJ .
AIDS, 1998, 12 (18) :2407-2415
[4]   Recombinant vaccine-induced protection against the highly pathogenic simian immunodeficiency virus SIVmac251:: Dependence on route of challenge exposure [J].
Benson, J ;
Chougnet, C ;
Robert-Guroff, M ;
Montefiori, D ;
Markham, P ;
Shearer, G ;
Gallo, RC ;
Cranage, M ;
Paoletti, E ;
Limbach, K ;
Venzon, D ;
Tartaglia, J ;
Franchini, G .
JOURNAL OF VIROLOGY, 1998, 72 (05) :4170-4182
[5]   MHC-I-restricted presentation of HIV-1 virion antigens without viral replication [J].
Buseyne, F ;
Le Gall, S ;
Boccaccio, C ;
Abastado, JP ;
Lifson, JD ;
Arthur, LO ;
Rivière, Y ;
Heard, JM ;
Schwartz, O .
NATURE MEDICINE, 2001, 7 (03) :344-349
[6]   Venezuelan equine encephalitis virus vectors expressing HIV-1 proteins: vector design strategies for improved vaccine efficacy [J].
Caley, IJ ;
Betts, MR ;
Davis, NL ;
Swanstrom, R ;
Frelinger, JA ;
Johnston, RE .
VACCINE, 1999, 17 (23-24) :3124-3135
[7]   Humoral, mucosal, and cellular immunity in response to a human immunodeficiency virus type 1 immunogen expressed by a Venezuelan equine encephalitis virus vaccine vector [J].
Caley, IJ ;
Betts, MR ;
Irlbeck, DM ;
Davis, NL ;
Swanstrom, R ;
Frelinger, JA ;
Johnston, RE .
JOURNAL OF VIROLOGY, 1997, 71 (04) :3031-3038
[8]   Alphavirus replicon particles as candidate HIV vaccines [J].
Davis, NL ;
West, A ;
Reap, E ;
MacDonald, G ;
Collier, M ;
Dryga, S ;
Maughan, M ;
Connell, M ;
Walker, C ;
McGrath, K ;
Cecil, C ;
Ping, LH ;
Frelinger, J ;
Olmsted, R ;
Keith, P ;
Swanstrom, R ;
Williamson, C ;
Johnson, P ;
Montefiori, D ;
Johnston, RE .
IUBMB LIFE, 2002, 53 (4-5) :209-211
[9]   Induction of long-term memory CD8+ T cells for recall of viral clearing responses against influenza virus [J].
Deliyannis, G ;
Jackson, DC ;
Ede, NJ ;
Zeng, WG ;
Hourdakis, I ;
Sakabetis, E ;
Brown, LE .
JOURNAL OF VIROLOGY, 2002, 76 (09) :4212-4221
[10]   Comparison of vaccine strategies using recombinant env-gag-pol MVA with or without an oligomeric env protein boost in the SHIV rhesus macaque model [J].
Earl, PL ;
Wyatt, LS ;
Montefiori, DC ;
Bilska, M ;
Woodward, R ;
Markham, PD ;
Malley, JD ;
Vogel, TU ;
Allen, TM ;
Watkins, DI ;
Miller, N ;
Moss, B .
VIROLOGY, 2002, 294 (02) :270-281